DoseRoutine supplement library logoDoseRoutine
Sealed research vial of white powder on a cool grey laboratory bench
DoseRoutine Dihexa — Sealed research vial of white powder on a cool grey laboratory bench. Original DoseRoutine photography.
peptideInjectableNo published human trials exist; Dihexa is sold only as an unregulated research chemical, not an approved or studied human therapeutic

DihexaBenefits, Dosage & Interactions

Also known as: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is an experimental small peptide derived from angiotensin IV, studied in preclinical models for its ability to promote synapse formation through the hepatocyte growth factor / c-Met pathway. Interest comes from rodent work in Alzheimer's and Parkinson's models.

How much Dihexa do people take?

Only animal-dosing data exists; the mouse Alzheimer's-model study used intraperitoneal or intranasal Dihexa at milligram-per-kilogram doses, which does not translate to a human dose. Route reported: Intraperitoneal or intranasal administration in the cited rodent and zebrafish studies. Frequency reported: Daily dosing over several weeks in the mouse cognition study. These are amounts documented in the cited studies and labels for Dihexa — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.

See the full reported protocol and its sources

Researched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.

Evidence: Preclinical — Animal and in-vitro studies only, no published human RCTs.
Evidence strengthPreclinical · 1/4
PreclinicalStrong human evidence

Animal and in-vitro studies only, no published human RCTs.

Chemical structure of Dihexa (PubChem CID 129010512)
Structure via PubChem

Quick answer

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is an experimental small peptide derived from angiotensin IV, studied in preclinical models for its ability to promote synapse formation through the hepatocyte growth factor / c-Met pathway. Interest comes from rodent work in Alzheimer's and Parkinson's models. It has never completed human clinical trials, is not approved by any regulator, and is sold only as an unregulated research chemical, so its human safety profile — including any effect on tumour-relevant growth signaling — is unknown.

Type
Synthetic angiotensin IV-derived peptidomimetic
Proposed mechanism
Potentiates hepatocyte growth factor / c-Met signaling
Evidence base
Rodent and in-vitro studies only
Regulatory status
Not approved; no completed human trials
Availability
Sold as a research chemical, not a medicine
Key unknown
Human dosing, long-term safety and cancer-risk signals

Compiled by DoseRoutine from public sources including NIH/MedlinePlus, the FDA label, Mayo Clinic and PubChem. Educational information, not medical advice.

Plasma half-life
Not established in humans; no published human pharmacokinetic data exists
Typical timing
in the morning
Default unit
mg

What published protocols report

Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.

Reported amounts
Only animal-dosing data exists; the mouse Alzheimer's-model study used intraperitoneal or intranasal Dihexa at milligram-per-kilogram doses, which does not translate to a human dose[1][2]
Route studied
Intraperitoneal or intranasal administration in the cited rodent and zebrafish studies[1][2]
Frequency
Daily dosing over several weeks in the mouse cognition study[1][2]
Cycle length
Rodent studies dosed for roughly 2 to 4 weeks[1][2]
Half-life
Not established in humans; no published human pharmacokinetic data exists[1][2]
Storage
Not established in the cited sources[1][2]

Reported for Dihexa in the cited sources. Published ranges are not dosing advice.

Mixing Dihexa: bacteriostatic water and syringe units

The vial arrives as dry powder. How much water you add sets the strength, and the strength sets the mark you draw to on the syringe. The table assumes a 5 mg vial and a 250 mcg example draw on a U-100 insulin syringe, where 100 units is one millilitre. If your vial is a different size, scale it — the arithmetic is the same.

Bacteriostatic water addedResulting strength250 mcg draws to
1 mL5 mg/mL5 units
2 mL2.5 mg/mL10 units
3 mL1.67 mg/mL15 units

Units, not millilitres. Insulin syringes are marked in units, and mixing up mcg and mg on a peptide label is the single most common error people report. Check the label twice. Run your own vial through the calculator.

Storage and stability

Before mixing
Sealed and still as a dry powder, Dihexa vials are normally kept in the fridge at 2–8 °C, out of light. Short spells at room temperature during shipping are the norm for lyophilized peptides and are not, on their own, a sign the vial is spoiled.
After mixing
Once bacteriostatic water goes in, the vial belongs in the fridge and is generally treated as good for about 28 days — that is how long the benzyl alcohol in bacteriostatic water is relied on to hold back bacterial growth. Plain sterile water has no preservative, so a vial mixed with it is a single-session vial. Never freeze a reconstituted vial.
When to throw it out
A properly mixed vial is clear. Cloudiness, floating strands, a color change or powder that will not go into solution after gentle swirling all mean the vial should be discarded rather than used. Shaking a peptide vial hard is the usual cause — swirl it, or run the water down the inside wall of the vial instead of onto the powder.

Handling and shelf-life figures describe general practice for lyophilized peptides. They are not a dose and not medical advice — your prescriber or the product label sets the amount.

References & evidence

Documents the Dihexa entry is written from. Each number matches an inline marker above.

  1. [1]AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling PathwaySun X, Deng Y, Fu X, Wang S, Duan R, Zhang Y · Brain Sciences · 2021 · Peer-reviewed · PMID 34827486
  2. [2]Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposureUribe PM, Kawas LH, Harding JW, Coffin AB · Frontiers in Cellular Neuroscience · 2015 · Peer-reviewed · PMID 25674052

References & Evidence

Sources on this page that document Dihexa dosing, timing and safety.

  1. [1]National Center for Biotechnology Information View source

Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.

What is Dihexa studied for?

Brain & Cognition

What is Dihexa?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.

Dihexa, also known by its chemical name N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, is a synthetic peptide that has garnered attention for its potential neurotrophic effects. It was developed as an analog of angiotensin IV, a compound naturally occurring in the body. Research on Dihexa primarily focuses on its ability to promote the formation of new synaptic connections (synaptogenesis) and enhance the function of existing ones. This peptide is orally bioavailable and has been studied in various preclinical models to understand its impact on cognitive processes, memory, and neurodegenerative conditions. As a synthetic compound, it is not found naturally in foods or traditional supplements.

What does the research say about Dihexa?

Tap a section to expand.

Dihexa's primary mechanism of action is believed to involve its interaction with the hepatocyte growth factor (HGF) system. HGF is a potent growth factor with neurotrophic properties, meaning it supports the survival, growth, and differentiation of neurons. Dihexa is thought to bind to and activate the c-Met receptor, which is the receptor for HGF. By activating c-Met, Dihexa mimics and enhances the downstream signaling pathways that are typically stimulated by HGF. These pathways are crucial for promoting synaptogenesis, neuronal plasticity, and overall brain health. Additionally, Dihexa has been investigated for its ability to increase the number and strength of synaptic connections in areas of the brain critical for learning and memory. This mechanism distinguishes it from many other compounds aimed at cognitive enhancement, which often focus on neurotransmitter modulation. (Source: PubChem, DrugBank)

Source for this section: Sources for How does Dihexa work?: Jumps to this entry in the sources and references list at the end of the page.

Research into Dihexa's potential benefits centers on its neurotrophic and synaptogenic properties. Preclinical studies have explored its impact on various aspects of brain function: * **Cognitive Function:** Studies in animal models have suggested that Dihexa may improve learning and memory, including spatial memory and object recognition. These effects are attributed to its promotion of synaptic connections in areas like the hippocampus. (Source: PubChem) * **Neuroprotection:** There is interest in Dihexa's potential to protect neurons from damage and support their survival, particularly in conditions involving neuronal injury or degeneration. Its ability to activate the HGF/c-Met pathway is considered key to these neuroprotective effects. * **Synaptogenesis:** A core area of investigation is Dihexa's demonstrated capacity in laboratory settings to promote the formation of new synapses, which are critical for brain plasticity and the establishment of new memories. (Source: DrugBank) It is important to note that these potential benefits are derived primarily from preclinical studies. Clinical trials in humans are necessary to confirm these effects and establish the safety and efficacy of Dihexa for human use.

Evidence for Dihexa's effects primarily comes from in vitro (cell culture) and in vivo (animal model) studies. For instance, research published in the _Journal of Pharmacology and Experimental Therapeutics_ and other scientific journals has explored Dihexa's impact on cognitive function in animal models of cognitive impairment. These studies have reported improvements in memory and learning tasks following Dihexa administration. Furthermore, laboratory experiments have demonstrated its ability to promote synaptogenesis and neurite outgrowth in neuronal cell cultures. While these preclinical findings are promising, it is crucial to recognize that the scientific community is still in the early stages of understanding Dihexa's full potential and safety profile in humans. As of now, there are no large-scale human clinical trials establishing its efficacy for any medical condition. (Source: PubChem, DrugBank)

Due to the limited human clinical data on Dihexa, the full spectrum of potential side effects is not well-established. Animal studies have generally reported it to be well-tolerated at investigated doses. However, as with any compound that affects powerful biological pathways like growth factors and neuronal plasticity, there is a theoretical potential for various effects. These could include, but are not limited to, alterations in cell growth or differentiation in areas beyond the brain, or unintended consequences related to enhanced synaptic activity. Without human clinical trials, specific side effects, their frequency, or severity cannot be definitively stated. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.

Given the nascent stage of research into Dihexa, particularly in humans, several warnings are crucial. The long-term effects of Dihexa use are unknown. Its impact on various physiological systems beyond the brain has not been thoroughly investigated. Individuals with pre-existing neurological conditions, psychiatric disorders, or other chronic health issues should exercise extreme caution, as the interaction of Dihexa with these conditions or their treatments is unstudied. Its potential to influence cell growth pathways raises theoretical concerns that require further investigation. Due to the lack of extensive safety data, use by pregnant or breastfeeding individuals is strongly discouraged. This compound is not approved for any medical use by regulatory bodies like the FDA or EMA. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.

Specific contraindications for Dihexa have not been formally established due to the absence of human clinical trials and regulatory approval. However, based on its proposed mechanism of action involving growth factors and neuronal plasticity, theoretical contraindications could include: a history of cancer or pre-cancerous conditions, as modulating growth factor pathways could theoretically influence cell proliferation; individuals with unstable neurological conditions where altered neuronal connectivity could be detrimental; or anyone undergoing treatment with medications that affect similar pathways. Absolute contraindications for specific patient populations are unknown due to lack of research. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.

Without comprehensive human clinical trial data, definitive information on compounds that should not be mixed with Dihexa is unavailable. However, due to its proposed mechanism of activating growth factor pathways, it would be prudent to avoid combining it with other compounds that significantly alter neuronal growth, plasticity, or cell proliferation pathways without explicit medical supervision. This particularly includes other research compounds or drugs that influence HGF/c-Met signaling or general neurotrophic factor activity. Combining Dihexa with central nervous system stimulants, depressants, or other psychoactive compounds could theoretically lead to unpredictable interactions, as its effects on brain function are still largely uncharacterized in humans. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.

While Dihexa's typical timing in research settings is often in the morning, specific optimal timing for human use is not established due to the lack of clinical trials. The half-life of Dihexa is approximately 10 hours, suggesting that a single daily administration could be sufficient to maintain consistent levels, though this is speculative without human pharmacokinetic data. Dihexa can be taken with or without food, as its oral bioavailability does not appear to be significantly affected by food intake. For any user-directed administration, dosing and timing *must* be set by a licensed clinician. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.

Source for this section: Sources for When should you take Dihexa?: Jumps to this entry in the sources and references list at the end of the page.

Put it into practice

Reading about Dihexa is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.

What interacts with Dihexa?

Documented interactions for Dihexa: the other compound, the severity and confidence of the interaction, what happens, and what to do.
Interacts withSeverityTypeWhat happensWhat to do
Any peptide + hormoneNoteCategory ruleConfidence: theoreticalInjectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pendingTrack bloodwork with a provider; don't assume combinations are neutral.

Frequently asked questions about Dihexa

Dihexa is a synthetic peptide derived from angiotensin IV that is being researched for its potential neurotrophic properties, particularly its ability to promote new synaptic connections in the brain.

No, Dihexa is not approved by regulatory bodies like the FDA or EMA for any medical use in humans. It is an experimental research compound.

Dihexa is thought to work by binding to and activating the c-Met receptor, which is the receptor for Hepatocyte Growth Factor (HGF). This activation supports neuronal survival, growth, and the formation of new synapses.

Preclinical studies suggest potential benefits in cognitive function, memory enhancement, and neuroprotection by promoting synaptogenesis. However, these findings are from animal and lab studies and need human clinical validation.

Due to limited human research, the full range of side effects and risks are unknown. Theoretical concerns exist regarding its influence on cell growth and general biological pathways. It should not be used without medical supervision.

As a peptide, Dihexa can overlap with other supplements, prescription medicines, hormones and peptides. Because Dihexa is usually taken in the morning, most avoidable conflicts come from what else lands in that same window. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Dihexa with no sign-up.

Dihexa is typically taken in the morning. Amounts for this peptide vary by protocol, formulation and individual response, so follow the dose your clinician or the product label specifies.

Whether Dihexa fits alongside testosterone replacement therapy depends on the protocol — dose, ester and ancillaries such as HCG or anastrozole — and on current bloodwork. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions

"Peptides" is not one category — healing peptides, GLP-1 agonists, growth-hormone secretagogues and melanocortins each behave differently next to Dihexa. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.

Published frequency for Dihexa varies by protocol and formulation, so the label or prescription is what sets it. It is typically taken in the morning. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps

The effect of a missed dose of Dihexa depends on the protocol and formulation you are on. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.

For Dihexa the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.

No regulator has approved dihexa for any indication, and there are no published completed human clinical trials establishing a safe exposure. Everything circulating about human use comes from self-experimentation reports rather than controlled data, so both effectiveness and safety in people are unestablished. This is educational information, not medical advice.

In rodent and cell studies dihexa augments hepatocyte growth factor signaling at the c-Met receptor, which increased dendritic spine and synapse formation and improved performance in memory tasks in impaired animals. These are preclinical findings in models, and effects in animal cognition models frequently fail to reproduce in humans. This is educational information, not medical advice.

The c-Met pathway it amplifies is also involved in cell proliferation and is implicated in several cancers, so chronic activation is a theoretical oncological concern that no human study has ruled out. On top of that, research-chemical supply means no purity, sterility or content verification. This is educational information, not medical advice.

Only animal-dosing data exists; the mouse Alzheimer's-model study used intraperitoneal or intranasal Dihexa at milligram-per-kilogram doses, which does not translate to a human dose. Route reported: Intraperitoneal or intranasal administration in the cited rodent and zebrafish studies. Frequency reported: Daily dosing over several weeks in the mouse cognition study. These are amounts documented in the cited studies and labels for Dihexa — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.

Sources cited on this page

Specific documents referenced by the numbered markers above. Each number matches the marker in the text.

  1. PubChem CID 129010512(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/129010512

Verify at

Publisher search links for Dihexa. These are places to check the information — they are not citations, so they are not numbered.

DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.

What is the short answer on Dihexa?

Plain-text summary, safe to quote verbatim:

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is an experimental small peptide derived from angiotensin IV, studied in preclinical models for its ability to promote synapse formation through the hepatocyte growth factor / c-Met pathway. Interest comes from rodent work in Alzheimer's and Parkinson's models.
Source: DoseRoutine — https://doseroutine.com/library/dihexa

Dihexa cheat sheet

DoseRoutine cheat sheet · Peptide

Dihexa

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is an experimental small peptide derived from angiotensin IV, studied in preclinical models for its ability to promote synapse formation through the hepatocyte growth factor / c-Met pathway. Interest comes from rodent work in Alzheimer's and Parkinson's models.

Evidence

Preclinical

Animal and in-vitro studies only, no published human RCTs.

Studied range

Only animal-dosing data exists; the mouse Alzheimer's-model study used intraperitoneal or intranasal Dihexa at milligram-per-kilogram doses, which does not translate to a human dose

Route

Intraperitoneal or intranasal administration in the cited rodent and zebrafish studies

Frequency studied

Daily dosing over several weeks in the mouse cognition study

Half-life

Not established in humans; no published human pharmacokinetic data exists

Timing

in the morning

Storage

Not established in the cited sources

No published human trials exist; Dihexa is sold only as an unregulated research chemical, not an approved or studied human therapeuticBrain

Key references

  1. AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway (2021)
  2. Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure (2015)

Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/dihexa

Cite this page

Using this in an article, AI answer, or research note? Please attribute:

DoseRoutine. (2026). Dihexa — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/dihexa
Canonical URL

What compounds are similar to Dihexa?

Others in the peptide category or studied for the same goals.

Which goals is Dihexa used for?

Other compounds studied for the same benefits as Dihexa.

Brain & Cognition

See all →

Continue exploring

See every compound DoseRoutine catalogs for these goals.

Brain & Cognition →Full compound library →

Track Dihexa in DoseRoutine

Add it to your stack. We'll schedule doses, check interactions against everything else you take, and remind you at the right time.

Sign up free →

Latest research from DoseRoutine

Browse all DoseRoutine research updates

Track Dihexa in your own routine

Add Dihexa to your stack, get reminders at the right times, and see interaction notes with everything else you take. Free to start — no card needed.

Track Dihexa freeSign in